|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chalela R, Curull V, Enríquez C, Pijuan L,
Bellosillo B and Gea J: Lung adenocarcinoma: From molecular basis
to genome-guided therapy and immunotherapy. J Thorac Dis.
9:2142–2158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoh K, Seto T, Satouchi M, Nishio M,
Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, et
al: Vandetanib in patients with previously treated RET-rearranged
advanced non-small-cell lung cancer (LURET): An open-label,
multicentre phase 2 trial. Lancet Respir Med. 5:42–50. 2017.
View Article : Google Scholar
|
|
5
|
Serizawa M, Koh Y, Kenmotsu H, Isaka M,
Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, et al:
Assessment of mutational profile of Japanese lung adenocarcinoma
patients by multitarget assays: A prospective, single-institute
study. Cancer. 120:1471–1481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stephen AG, Esposito D, Bagni RK and
McCormick F: Dragging ras back in the ring. Cancer Cell.
25:272–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jänne PA, van den Heuvel MM, Barlesi F,
Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido
P, et al: Selumetinib plus docetaxel compared with docetaxel alone
and progression-free survival in patients with KRAS-mutant advanced
non-small cell lung cancer: The SELECT-1 Randomized Clinical Trial.
JAMA. 317:1844–1853. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blumenschein GR Jr, Smit EF, Planchard D,
Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH,
et al: A randomized phase II study of the MEK1/MEK2 inhibitor
trametinib (GSK1120212) compared with docetaxel in KRAS- mutant
advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 26:894–901.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
15
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adida C, Berrebi D, Peuchmaur M,
Reyes-Mugica M and Altieri DC: Anti-apoptosis gene, survivin, and
prognosis of neuroblastoma. Lancet. 351:882–883. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
18
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
19
|
Monzó M, Rosell R, Felip E, Astudillo J,
Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A and Abad A: A
novel anti-apoptosis gene: Re-expression of survivin messenger RNA
as a prognosis marker in non-small-cell lung cancers. J Clin Oncol.
17:2100–2104. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaopotong P, Kajita S, Hashimura M and
Saegusa M: Nuclear survivin is associated with cell proliferative
advantage in uterine cervical carcinomas during radiation therapy.
J Clin Pathol. 65:424–430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Als AB, Dyrskjøt L, von der Maase H, Koed
K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen
KM, et al: Emmprin and survivin predict response and survival
following cisplatin-containing chemotherapy in patients with
advanced bladder cancer. Clin Cancer Res. 13:4407–4414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang W, Mao Y, Zhan Y, Huang J, Wang X,
Luo P, Li LI, Mo D, Liu Q, Xu H, et al: Prognostic implications of
survivin and lung resistance protein in advanced non-small cell
lung cancer treated with platinum-based chemotherapy. Oncol Lett.
11:723–730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zaffaroni N and Daidone MG: Survivin
expression and resistance to anticancer treatments: Perspectives
for new therapeutic interventions. Drug Resist Updat. 5:65–72.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yilmaz A, Mohamed N, Patterson KA, Tang Y,
Shilo K, Villalona-Calero MA, Davis ME, Zhou X, Frankel W, Otterson
GA, et al: Increased NQO1 but not c-MET and survivin expression in
non-small cell lung carcinoma with KRAS mutations. Int J Environ
Res Public Health. 11:9491–9502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi T, Hosono Y, Yanagisawa K and
Takahashi T: NKX2-1/TTF-1: An enigmatic oncogene that functions as
a double-edged sword for cancer cell survival and progression.
Cancer Cell. 23:718–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsukuma S, Yoshihara M, Suda T, Shiozawa
M, Akaike M, Ishikawa T, Koizume S, Sakuma Y and Miyagi Y:
Differential detection of KRAS mutations in codons 12 and 13 with a
modified loop-hybrid (LH) mobility shift assay using an insert-
type LH-generator. Clin Chim Acta. 412:1874–1878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yatabe Y, Kosaka T, Takahashi T and
Mitsudomi T: EGFR mutation is specific for terminal respiratory
unit type adenocarcinoma. Am J Surg Pathol. 29:633–639. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar
|
|
29
|
Yamaguchi M, Hirai S, Tanaka Y, Sumi T,
Miyajima M, Mishina T, Yamada G, Otsuka M, Hasegawa T, Kojima T, et
al: Fibroblastic foci, covered with alveolar epithelia exhibiting
epithelial-mesenchymal transition, destroy alveolar septa by
disrupting blood flow in idiopathic pulmonary fibrosis. Lab Invest.
97:232–242. 2017. View Article : Google Scholar
|
|
30
|
Sakuma Y, Nishikiori H, Hirai S, Yamaguchi
M, Yamada G, Watanabe A, Hasegawa T, Kojima T, Niki T and Takahashi
H: Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung
adenocarcinoma cells with an epithelial-mesenchymal transition
phenotype. Lab Invest. 96:391–398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sakuma Y, Matsukuma S, Nakamura Y,
Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y,
Yokose T, et al: Enhanced autophagy is required for survival in
EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest.
93:1137–1146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee GY, Kenny PA, Lee EH and Bissell MJ:
Three-dimensional culture models of normal and malignant breast
epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shibue T and Weinberg RA: Integrin
beta1-focal adhesion kinase signaling directs the proliferation of
metastatic cancer cells disseminated in the lungs. Proc Natl Acad
Sci USA. 106:10290–10295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y
and Sakai T: Antitumor activities of JTP-74057 (GSK1120212), a
novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro
and in vivo. Int J Oncol. 39:23–31. 2011.PubMed/NCBI
|
|
36
|
Kitai H, Ebi H, Tomida S, Floros KV,
Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC and Yano S:
Epithelial-to-mesenchymal transition defines feedback activation of
receptor tyrosine kinase signaling induced by MEK inhibition in
KRAS-mutant lung cancer. Cancer Discov. 6:754–769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang J, Wang Y, Shao L, Laberge RM,
Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W,
et al: Clearance of senescent cells by ABT263 rejuvenates aged
hematopoietic stem cells in mice. Nat Med. 22:78–83. 2016.
View Article : Google Scholar :
|
|
38
|
Corcoran RB, Cheng KA, Hata AN, Faber AC,
Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et
al: Synthetic lethal interaction of combined BCL-XL and MEK
inhibition promotes tumor regressions in KRAS mutant cancer models.
Cancer Cell. 23:121–128. 2013. View Article : Google Scholar :
|
|
39
|
Ikehara M, Oshita F, Kameda Y, Ito H,
Ohgane N, Suzuki R, Saito H, Yamada K, Noda K and Mitsuda A:
Expression of survivin correlated with vessel invasion is a marker
of poor prognosis in small adenocarcinoma of the lung. Oncol Rep.
9:835–838. 2002.PubMed/NCBI
|
|
40
|
Wang M, Liu BG, Yang ZY, Hong X and Chen
GY: Significance of survivin expression: Prognostic value and
survival in stage III non-small cell lung cancer. Exp Ther Med.
3:983–988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oshita F, Ito H, Ikehara M, Ohgane N,
Hamanaka N, Nakayama H, Saito H, Yamada K, Noda K, Mitsuda A, et
al: Prognostic impact of survivin, cyclin D1, integrin beta1, and
VEGF in patients with small adenocarcinoma of stage I lung cancer.
Am J Clin Oncol. 27:425–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun PL, Jin Y, Kim H, Seo AN, Jheon S, Lee
CT and Chung JH: Survivin expression is an independent poor
prognostic marker in lung adenocarcinoma but not in squamous cell
carcinoma. Virchows Arch. 463:427–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang D, Welm A and Bishop JM: Cell
division and cell survival in the absence of survivin. Proc Natl
Acad Sci USA. 101:15100–15105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dai D, Liang Y, Xie Z, Fu J, Zhang Y and
Zhang Z: Survivin deficiency induces apoptosis and cell cycle
arrest in HepG2 hepatocellular carcinoma cells. Oncol Rep.
27:621–627. 2012.
|
|
45
|
Yan X, Li P, Zhan Y, Qi M, Liu J, An Z,
Yang W, Xiao H, Wu H, Qi Y, et al: Dihydroartemisinin suppresses
STAT3 signaling and Mcl-1 and Survivin expression to potentiate
ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells
harboring EGFR or RAS mutation. Biochem Pharmacol. 150:72–85. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Coello MC, Luketich JD, Litle VR and
Godfrey TE: Prognostic significance of micrometastasis in
non-small-cell lung cancer. Clin Lung Cancer. 5:214–225. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sakuma Y: Epithelial-to-mesenchymal
transition and its role in EGFR-mutant lung adenocarcinoma and
idiopathic pulmonary fibrosis. Pathol Int. 67:379–388. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hwang DH, Sholl LM, Rojas-Rudilla V, Hall
DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL,
Kuo FC, et al: KRAS and NKX2-1 mutations in invasive mucinous
adenocarcinoma of the lung. J Thorac Oncol. 11:496–503. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Matsubara D, Soda M, Yoshimoto T, Amano Y,
Sakuma Y, Yamato A, Ueno T, Kojima S, Shibano T, Hosono Y, et al:
Inactivating mutations and hypermethylation of the NKX2-1/TTF-1
gene in non-terminal respiratory unit-type lung adenocarcinomas.
Cancer Sci. 108:1888–1896. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamaguchi T, Yanagisawa K, Sugiyama R,
Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H,
et al: NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR
survival signaling in lung adenocarcinoma. Cancer Cell. 21:348–361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Maeda Y, Tsuchiya T, Hao H, Tompkins DH,
Xu Y, Mucenski ML, Du L, Keiser AR, Fukazawa T, Naomoto Y, et al:
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous
adenocarcinoma of the lung. J Clin Invest. 122:4388–4400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang T, Zhang T, Han X, Liu XI, Zhou N and
Liu Y: Impact of the International Association for the Study of
Lung Cancer/American Thoracic Society/European Respiratory Society
classification of stage IA adenocarcinoma of the lung: Correlation
between computed tomography images and EGFR and KRAS gene
mutations. Exp Ther Med. 9:2095–2103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rudin CM, Hann CL, Garon EB, Ribeiro de
Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D,
Ramalingam SS, et al: Phase II study of single-agent navitoclax
(ABT-263) and biomarker correlates in patients with relapsed small
cell lung cancer. Clin Cancer Res. 18:3163–3169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kipps TJ, Eradat H, Grosicki S, Catalano
J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S,
Punnoose E, et al: A phase 2 study of the BH3 mimetic BCL2
inhibitor navitoclax (ABT-263) with or without rituximab, in
previously untreated B-cell chronic lymphocytic leukemia. Leuk
Lymphoma. 56:2826–2833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Infante JR, Fecher LA, Falchook GS,
Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y,
Morris SR, et al: Safety, pharmacokinetic, pharmacodynamic, and
efficacy data for the oral MEK inhibitor trametinib: A phase 1
dose-escalation trial. Lancet Oncol. 13:773–781. 2012. View Article : Google Scholar : PubMed/NCBI
|
